# US 2023/0404958 A1 · Agent for inhibiting renal damage induced by rhabdomyolysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404958 A1
- Document ID: US20230404958A1
- Status: Published application
- Kind: A1
- Application number: 18/247,415
- Filed: 2022-03-08
- Published: 2023-12-21
- Earliest claimed: 2021-03-12
- Assignees: Niigata University; Denka Company Limited
- Applicants: Niigata University; Denka Company Limited
- Inventors: Akihiko SAITO; Sawako GOTO; Yoshiaki HIRAYAMA
- Web page: https://patentgrep.com/patent/US20230404958A1

## CPC

- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One object of the present invention is to provide an inhibitor for renal injuries induced by rhabdomyolysis. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

## Claims

### Claim 1

A method for inhibiting a renal injury, the method comprising administering to a subject in need thereof an inhibitor comprising cilastatin or a pharmaceutically acceptable salt thereof as an active component wherein the renal injury comprises a rhabdomyolysis induced renal injury.

### Claim 2 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the inhibitor is administered in an injectable form.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein from 0.01 mg to 100 mg of the inhibitor is administered to the subject.

### Claim 5 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein from 0.1 mg to 10 mg of the inhibitor is administered to the subject.

### Claim 6 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the pharmaceutically acceptable comprises an alkali metal salt, an alkali earth metal salt, an organic amine salt, an ammonium salt, or a basic amino acid salt.

### Claim 7 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the pharmaceutically acceptable salt comprises lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt; zinc salt, aluminum salt, choline salt, ethanolamine salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, dibenzylamine salt, phenethylbenzylamine salt, procaine salt, morpholine salt, pyridine salt, piperidine salt, piperadine salt, N-ethylpiperidine salt, lysine salt, arginine salt, or a combination thereof.

### Claim 8 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the pharmaceutically acceptable salt comprises cilastatin sodium.

### Claim 9 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the rhabdomyolysis induced renal injury comprises nephropathy, renal injury, nephritis, renal failure, renal disease, acute nephropathy, acute kidney injury, acute nephritis, acute renal failure, acute renal disease, chronic nephropathy, chronic renal injury, chronic nephritis, chronic renal failure, chronic kidney disease, tubular nephropathy, tubular renal injury, tubular nephritis, tubular renal failure, tubular renal disease, tubulointerstitial nephropathy, tubulointerstitial renal injury, tubulointerstitial nephritis, tubulointerstitial renal failure, tubulointerstitial renal disease, obstructive nephropathy, obstructive renal injury, obstructive nephritis, obstructive renal failure, obstructive renal disease, acute nephritic syndrome, rapidly progressive nephritic syndrome, chronic nephritic syndrome, nephrotic syndrome, renal vasospasm, acute tubular necrosis, or a combination thereof.

### Claim 10 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the inhibitor is administered in the form of a powder, granule, capsule, or a chewable tablet.

### Claim 11 (depends on 1)

The method for inhibiting a renal injury according to claim 1, wherein the inhibitor is administered in the form of a solution, a syrup, or a spray.

### Claim 12

A method for inhibiting myoglobin uptake into kidney tissues, the method comprising administering to a subject in need thereof an inhibitor comprising cilastatin or a pharmaceutically acceptable salt thereof as an active component.

### Claim 13 (depends on 12)

The method for inhibiting myoglobin uptake into kidney tissues according to claim 12, wherein from 0.01 mg to 100 mg of the inhibitor is administered to the subject.

### Claim 14 (depends on 12)

The method for inhibiting myoglobin uptake into kidney tissues according to claim 12, wherein from 0.1 mg to 10 mg of the inhibitor is administered to the subject.

### Claim 15 (depends on 12)

The method for inhibiting myoglobin uptake into kidney tissues according to claim 12, wherein the pharmaceutically acceptable salt comprises an alkali metal salt, an alkali earth metal salt, an organic amine salt, an ammonium salt, or a basic amino acid salt.

### Claim 16 (depends on 12)

The method for inhibiting myoglobin uptake into kidney tissues according to claim 12, wherein the pharmaceutically acceptable salt comprises lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt; zinc salt, aluminum salt, choline salt, ethanolamine salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, dibenzylamine salt, phenethylbenzylamine salt, procaine salt, morpholine salt, pyridine salt, piperidine salt, piperadine salt, N-ethylpiperidine salt, lysine salt arginine salt, or a combination thereof.

### Claim 17 (depends on 12)

The method for inhibiting myoglobin uptake into kidney tissues according to claim 12, wherein the pharmaceutically acceptable salt comprises cilastatin sodium.

### Claim 18 (depends on 12)

The method for inhibiting myoglobin uptake into kidney tissues according to claim 12, wherein the rhabdomyolysis induced renal injury comprises nephropathy, renal injury, nephritis, renal failure, renal disease, acute nephropathy, acute kidney injury, acute nephritis, acute renal failure, acute renal disease, chronic nephropathy, chronic renal injury, chronic nephritis, chronic renal failure, chronic kidney disease, tubular nephropathy, tubular renal injury, tubular nephritis, tubular renal failure, tubular renal disease, tubulointerstitial nephropathy, tubulointerstitial renal injury, tubulointerstitial nephritis, tubulointerstitial renal failure, tubulointerstitial renal disease, obstructive nephropathy, obstructive renal injury, obstructive nephritis, obstructive renal failure, obstructive renal disease, acute nephritic syndrome, rapidly progressive nephritic syndrome, chronic nephritic syndrome, nephrotic syndrome, renal vasospasm, acute tubular necrosis, or a combination thereof.
